missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Description
Immunogen sequence: VEFGGNDLLQ VYNAQQIKHR LNSTGMYVAN TKPGGFTIEI SNNNSTMVMT GMRIQIGTQA IERAPSYIEI FGRTMQLNLS RSRWFDFPFT REEALQADKK LNLFIGASVD PAGVTMIDAV KIYGKTKEQF Highest antigen sequence identity to the following orthologs: Mouse - 98%, Rat - 98%.
E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. Together with clathrin, forms meshwork structures involved in membrane morphogenesis and cytoskeletal organization. Regulates integrin-mediated signaling. May play a role in activation of FAK in response to cell-matrix interactions. Mediates ubiquitination of ACLY, leading to its subsequent degradation.
Specifications
Specifications
| Antigen | UBR4 |
| Applications | Immunohistochemistry (Paraffin) |
| Classification | Polyclonal |
| Concentration | 0.1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 |
| Gene | UBR4 |
| Gene Accession No. | Q5T4S7 |
| Gene Alias | 1810009A16Rik; 600 kDa retinoblastoma protein-associated factor; A930005E13Rik; D930005K06Rik; E3 ubiquitin-protein ligase UBR4; Gm1032; Gm1666; KIAA0462; KIAA1307; mKIAA0462; N28143; N-recognin-4; p600; Rbaf600; retinoblastoma-associated factor 600; retinoblastoma-associated factor 600-like protein; retinoblastoma-associated factor of 600 kDa; RING-type E3 ubiquitin transferase UBR4; ubiquitin protein ligase E3 component n-recognin 4; UBR4; Zinc finger UBR1-type protein 1; zinc finger, UBR1 type 1; ZUBR1 |
| Gene Symbols | UBR4 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?